Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of L

JPMorgan Removes Akero Therapeutics (AKRO) from Analyst Focus List and Catalyst Watch, PT $62

October 10, 2023 12:35 PM EDT

JPMorgan analyst Eric Joseph reiterated an Overweight rating and $62.00 price target on Akero Therapeutics (NASDAQ: AKRO).

The analyst comments "In our view, the totality of the SYMMETRY dataset continues to support EFX having a differentiated impact on histology across the spectrum of... More

Akero Therapeutics (AKRO) declines after efruxifermin NASH trial readout disappoints; Is it time to buy?

October 10, 2023 8:26 AM EDT

Shares Akero Therapeutics (NASDAQ: AKRO) declined after it reported analysis of data from its study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). The stock declined as much as 60% shortly after the data release.

The drug missed its primary endpoint but efficacy trends were positive in a tough population, and the selloff in shares could be an overreaction, said analysts at Cantor Fitzgerald.

Canaccord Genuity analysts said they would be strong buyers... More

Canaccord on Akero Therapeutics (AKRO): 'We would be strong buyers on this weakness'

October 10, 2023 8:21 AM EDT

Canaccord Genuity analyst Edward Nash reiterated a Buy rating and $59.00 price target on Akero Therapeutics (NASDAQ: AKRO)

The analyst comments "Akero Therapeutics reports 36-week analysis of SYMMETRY, a 96-week Phase IIb study evaluating the efficacy and safety of its lead product candidate efruxifermin... More

Cantor Fitzgerald on Akero Therapeutics (AKRO), 'we expect the stock to trade down'

October 10, 2023 7:55 AM EDT

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating and $69.00 price target on Akero Therapeutics (NASDAQ: AKRO)

The analyst comments "EFX efficacy meets our mixed scenario, and we expect the stock to trade down (premarket stock is trading down 50%+, which seems an... More

89bio Inc. (ETNB) Trades Lower in Sympathy with Akero Therapeutics (AKRO)

October 10, 2023 7:17 AM EDT

89bio Inc. (NASDAQ: ETNB) Trades Lower in Sympathy with Akero Therapeutics (NASDAQ: AKRO)

Akero -63% Following NASH DataETNB -40%... More

Akero Therapeutics (AKRO) Falls 48% Following 6-Week Analysis of 96-Week Phase 2b SYMMETRY Study for NASH

October 10, 2023 7:07 AM EDT

Akero Therapeutics (NASDAQ: AKRO) Falls 48% Following 6-Week Analysis of 96-Week Phase 2b SYMMETRY Study for NASH

22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to... More